Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database

Documenti analoghi

• Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System
  di: Guanghan Sun, et al.
  Pubblicazione: (2025)
• Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database
  di: Yuko Kanbayashi, et al.
  Pubblicazione: (2024)
• Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis
  di: Haiyang Li, et al.
  Pubblicazione: (2024)
• Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
  di: Lan Luo, et al.
  Pubblicazione: (2025)
• Exploring Definity‐related adverse reaction: A real‐world pharmacovigilance study via FAERS database analysis
  di: Wenrong Lin, et al.
  Pubblicazione: (2025)